XON 7
Alternative Names: XON-7Latest Information Update: 28 Jan 2026
At a glance
- Originator Xenothera
- Class Antibodies; Antineoplastics; Immunotherapies; Polyclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Breast cancer; Soft tissue sarcoma
- No development reported Haematological malignancies
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for phase-I development in Haematological-malignancies in France (Parenteral)
- 25 Apr 2025 Preclinical trials in Breast cancer in France (Parenteral)
- 25 Apr 2025 Pharmacodynamics data from a preclinical study for Breast cancer presented at the 116th American Association for Cancer Research Annual Meeting (AACR-2025)